ClinicalTrials.gg
CompletedNCT04072952mBCUpdated Sep 29, 2026Results posted

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

A Phase 1/2 interventional study of Vepdegestrant and Vepdegestrant in Breast Cancer, sponsored by Arvinas Estrogen Receptor, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Arvinas Estrogen Receptor, Inc. · Phase 1/2, Interventional, and Treatment

Updated Sep 29, 2026Results postedStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
219
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.

Enrollment
3rd of 12
219 · median 48
Started
2019
the only one that year
Phase 1/2
5 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
2 of 12
Arvinas Estrogen Receptor, Inc.

Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 5 in phase 1/2, and was the 2nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vepdegestrant

vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing vepdegestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This was a Phase 1/2 dose escalation and cohort expansion study and assessed the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or mBC, who had received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Metastatic Breast Cancer
  • Malignant Neoplasm of the Breast
  • mBC
  • ER+/HER2-
  • Locally Advanced Breast Cancer
  • ARV-471
  • Vepdegestrant
  • Palbociclib
  • Ibrance
04

Who can participate

The criteria were revised on the registry on Sep 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A, Part B, and Part C:

  • Participants at least 18 years of age at the time of signing the .
  • Participants must have or cytologically confirmed ER+ and - advanced breast cancer for which standard curative therapy is no longer effective or does not exist.
  • Participants must have measurable or non- by (RECIST) (version1.1), with radiologic tumor assessments performed within 28 days of the first dose of therapy.
  • Participants must be willing to undergo a core of accessible tumor within 4 weeks prior to the initiation of study treatment and a follow-up biopsy on treatment for ER immunohistochemistry (IHC) testing and pharmacodynamics studies. (Patients without accessible tumor tissue may be eligible after discussion with the Medical Monitor.)
  • Women must be due to surgical or natural menopause.

Part A:

- Participants must have received at least 2 prior endocrine regimens in any setting (, adjuvant or advanced/) a CDK4/6 inhibitor and up to 3 prior regimens of cytotoxic chemotherapy in the locally advanced or metastatic setting.

Part B:

  • Participants must have received at least 1 prior endocrine regimen for a minimum of 6 months in the locally advanced or metastatic setting; if more than 1 prior endocrine regimen has been administered, only one of the regimens must have been administered for a minimum of 6 months in the locally advanced or metastatic setting
  • Participants must have received a CDK4/6 inhibitor
  • Participants must have received up to 1 prior regimen of cytotoxic chemotherapy in the locally advanced or metastatic setting

Part C:

  • Participants must have received at least one prior endocrine regimen.
  • Participants must have received no more than two prior chemotherapy regimens for advanced disease.

Exclusion criteria

Exclusion Criteria:

Part A, Part B, and Part C:

  • Participants with known symptomatic requiring (above physiologic replacement doses). Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to first dose of study drug, have discontinued high-dose corticosteroid treatment for these for at least 4 weeks and are neurologically stable as judged by the Investigator.
  • Receipt of prior anti-cancer or other therapy within 14 days prior to the first administration of study drug.
  • Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow. Palliative radiation for the alleviation of pain due to bone metastasis will be allowed during the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)

    Participants received vepdegestrant 30 milligrams (mg) orally once daily (QD) with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after the end of treatment (EOT) or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)

    Participants received vepdegestrant 60 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)

    Participants received vepdegestrant 100 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)

    Participants received vepdegestrant 120 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)

    Participants received vepdegestrant 180 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)

    Participants received vepdegestrant 200 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)

    Participants received vepdegestrant 360 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)

    Participants received vepdegestrant 500 mg QD or 250 mg twice daily (BID), orally with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)

    Participants received vepdegestrant 700 mg QD or as BID dose (400 mg in the morning and 300 mg in the evening), orally with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)

    Participants received vepdegestrant 200 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)

    Participants received vepdegestrant 500 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant

  • Experimental
    Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)

    Participants initially received vepdegestrant 180 mg tablets orally QD with food then upon availability of the 100-mg tablets was rounded up to 200 mg QD, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed up for survival after at least 3 months after the EOT or Follow-up visit (whichever occurred later).

    Drug: Vepdegestrant · Drug: Palbociclib

  • Experimental
    Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)

    Participants received vepdegestrant 200 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant · Drug: Palbociclib

  • Experimental
    Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)

    Participants received vepdegestrant 400 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant · Drug: Palbociclib

  • Experimental
    Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)

    Participants received vepdegestrant 500 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant · Drug: Palbociclib

  • Experimental
    Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)

    Participants initially received palbociclib 100 mg orally QD starting on C1D1, for 21 days followed by 7 days off and then received vepdegestrant 200 mg QD with food on C1D9, given continuously (28-day cycle). Palbociclib was administered alone from C1D1 to C1D8 prior to starting vepdegestrant on C1D9. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

    Drug: Vepdegestrant · Drug: Palbociclib

Interventions

  • Vepdegestrant administered QD for 28-day cycles

    Also known as: ARV-471

  • Vepdegestrant administered QD or BID for 28-day cycles.

    Also known as: ARV-471

  • Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days

    Also known as: IBRANCE®

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment

    DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.

    Time frame: Baseline (Day 1) up to C1D28

  2. Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEs

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. Serious AE (SAE) was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)

  3. Part B: Clinical Benefit Rate (CBR)

    CBR: percentage of participants with summation of complete response (CR), partial response (PR) or stable disease (SD) of 24 weeks duration or longer. CR: disappearance of all target lesions (TLs) and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the longest diameter (LD) of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.

    Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)

  4. Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment

    DLT was defined as any AE or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.

    Time frame: Baseline (Day 1) up to C1D28

  5. Part C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)

  6. Part C: Maximum Tolerated Dose (MTD)

    MTD is the highest dose of a drug that can be given to participants without causing unacceptable DLTs, as determined during a clinical study.

    Time frame: Baseline (Day 1) up to C1D28

Secondary outcomes

  1. Part A: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant and Its Epimer ARV-473

    AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1.

  2. Part A: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant and Its Epimer ARV-473

    AUClast was defined as area under the concentration-time curve from time 0 through the last quantifiable concentration (AUClast). Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1

  3. Part A: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant and Its Epimer ARV-473

    Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1

  4. Part A: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant and Its Epimer ARV- 473

    Cmin was defined as the minimum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15

  5. Part A: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant

    CL/F was defined as the apparent oral plasma clearance of vepdegestrant. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15

  6. Part A: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant and Its Epimer ARV- 473

    Tmax was defined as the time of maximum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (median) was not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1

  7. Part A: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant and Its Epimer ARV- 473

    Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1

  8. Part A: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant and Its Epimer ARV- 473

    Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1

  9. Part A: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) of Vepdegestrant and Its Epimer ARV-473

    Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1

  10. Part A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for Cmax (MRCmax).

    The epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1

  11. Part A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for AUCtau (MRAUCtau)

    The epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1

  12. Part A: Overall Response Rate (ORR) by Investigator Per RECIST v1.1

    ORR was defined as the percentage of participants with best overall response (BOR) of CR and PR as per Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1). BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.

    Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)

  13. Part A: Clinical Benefit Rate (CBR)

    CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.

    Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)

  14. Part A: Disease Control Rate (DCR)

    DCR: percentage of participants with CR, PR or SD. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. DCR was based on confirmed responses. Confirmed responses were at least 4 weeks after the criteria for response were first met.

    Time frame: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)

  15. Part A: Progression-Free Survival (PFS) Per RECIST v1.1

    PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Kaplan-Meier (KM) estimate was used for analysis.

    Time frame: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)

  16. Part A: Duration of Response

    DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

    Time frame: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 4 years and 6 months)

  17. Part B: Overall Response Rate (ORR) by Investigator Per RECIST v1.1

    ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version \[v\] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.

    Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)

  18. Part B: Progression-Free Survival (PFS) Per RECIST v1.1

    PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

    Time frame: From start of study treatment up to progressive disease or death (up to approximately 2 years and 11 months)

  19. Part B: Duration of Response

    DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

    Time frame: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 2 years and 11 months)

  20. Part B: Overall Survival

    OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis.

    Time frame: From start of study treatment up to death (up to approximately 2 years and 11 months)

  21. Part B: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 2 years and 11 months)

  22. Part B: Pre-dose Concentrations of Vepdegestrant and Its Epimer ARV-473

    Pre-dose Plasma concentrations of vepdegestrant and ARV-473 was reported. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Predose on C1D15 and C1D28 to C26D28

  23. Part C: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

    AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant \& ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant \& ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for drug-drug interaction (DDI) evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.

  24. Part C: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

    As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.

  25. Part C: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

    As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.

  26. Part C: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

    Cmin was defined as the minimum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.

  27. Part C: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant and Palbociclib

    As planned for Part C, PK data of vepdegestrant and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.

  28. Part C: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

    Tmax was defined as the time of maximum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.

  29. Part C: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

    Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.

  30. Part C: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

    Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.

  31. Part C: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) (Effective T1/2) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

    Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12, 24 hours post dose on C1D15 for arms with palbociclib 125 mg (each cycle is of 28 days)

  32. Part C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for Cmax (MRCmax)

    Epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant, ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1/C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21/C2D15. As per protocol, in 100 mg palbociclib administered arm, intensive PK sample collection not done on C1D21 was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.

  33. Part C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for AUCtau (MRAUCtau)

    Epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.

  34. Part C: Overall Response Rate (ORR) by Investigator Per RECIST v1.1

    ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version \[v\] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.

    Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)

  35. Part C: Clinical Benefit Rate (CBR)

    CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.

    Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)

  36. Part C: Progression-Free Survival (PFS) Per RECIST v1.1

    PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

    Time frame: From start of study treatment up to progressive disease or death (up to approximately 3 years and 9 months)

  37. Part C: Overall Survival

    OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis.

    Time frame: From start of study treatment up to death (up to approximately 3 years and 9 months)

  38. Part C: Duration of Response

    DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

    Time frame: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 3 years and 9 months)

07

Results

Posted Sep 29, 2026

Participant flow

Participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+, HER2-) locally Advanced or Metastatic Breast Cancer (mBC) who had received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting were enrolled at sites in the United States (US).

Dose Escalation(A:1648 Days,C:1368 Days)
Participant flow — Dose Escalation(A:1648 Days,C:1368 Days)
MilestonePart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Started3315778152240020300
Treated3314778152240020300
Received 180 mg in part c0000000000020000
Received 200 mg in part c0000000000010000
Completed0000000000000000
Not completed3315778152240020300
Withdrew: Death10455471520000100
Withdrew: Lost to follow-up0000000200000000
Withdrew: Withdrawal by subject0010001200000000
Withdrew: Disease progression1201000000000000
Withdrew: Miscellaneous1000100000000000
Withdrew: Ongoing at data cut-off01101147320020200
Dose Expansion (B: 1079 Days,C:1368 Day)
Participant flow — Dose Expansion (B: 1079 Days,C:1368 Day)
MilestonePart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Started000000000353602102117
Treated000000000353602102017
Completed0000000000000000
Not completed000000000353602102117
Withdrew: Death0000000001214050111
Withdrew: Lost to follow-up0000000003101010
Withdrew: Withdrawal by subject0000000002201011
Withdrew: Adverse event0000000000000001
Withdrew: Physician decision0000000000000001
Withdrew: Disease progression0000000000000007
Withdrew: Miscellaneous0000000000000012
Withdrew: Not treated0000000000000010
Withdrew: Ongoing at data cut-off0000000001819014064

Outcome measures

PrimaryPart A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment

DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.

Time frame:
Baseline (Day 1) up to C1D28
Reported as:
Count of participants · Participants
Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment
ParticipantsPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment000000000
PrimaryPart A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEs

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. Serious AE (SAE) was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEs
ParticipantsPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
TEAEs331477815213
Serious TEAEs113001221
Treatment-Related TEAEs031464613152
PrimaryPart B: Clinical Benefit Rate (CBR)

CBR: percentage of participants with summation of complete response (CR), partial response (PR) or stable disease (SD) of 24 weeks duration or longer. CR: disappearance of all target lesions (TLs) and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the longest diameter (LD) of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.

Time frame:
From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
Reported as:
Number · percentage of participants
Part B: Clinical Benefit Rate (CBR)
percentage of participantsPart B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)
Part B: Clinical Benefit Rate (CBR)37.1 (21.5 to 55.1)38.9 (23.1 to 56.5)
PrimaryPart C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment

DLT was defined as any AE or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.

Time frame:
Baseline (Day 1) up to C1D28
Reported as:
Count of participants · Participants
Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment
ParticipantsPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg (Initially 180 mg)+Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)
Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment000
PrimaryPart C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)
Reported as:
Count of participants · Participants
Part C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs
ParticipantsPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
TEAEs22132017
Serious TEAEs18146
Vepdegestrant-Related TEAEs21631714
Palbociclib-Related TEAEs22132017
PrimaryPart C: Maximum Tolerated Dose (MTD)

MTD is the highest dose of a drug that can be given to participants without causing unacceptable DLTs, as determined during a clinical study.

Time frame:
Baseline (Day 1) up to C1D28
Reported as:
Number · milligram
Part C: Maximum Tolerated Dose (MTD)
milligramPart C - Dose Escalation Participants
Part C: Maximum Tolerated Dose (MTD)NA
SecondaryPart A: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant and Its Epimer ARV-473

AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1.
Reported as:
Geometric mean · hour*nanogram per millilter (h*ng/mL)
Part A: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant and Its Epimer ARV-473
hour*nanogram per millilter (h*ng/mL)Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Vepdegestrant: C1D11713.4 ± 6.52552963.7 ± 33.3643767 ± 47.9416326.2 ± 21.2259580.3 ± 12.4579111.2 ± 47.687—12172 ± 32.121—16784 ± 28.24NA ± NA
Vepdegestrant: C1D154051.4 ± 25.5947323.7 ± 15.2768009.8 ± 40.06313714 ± 12.90319225 ± 31.7715810 ± 37.83622062 ± 28.84425931 ± 26.561NA ± NA34585 ± 35.453NA ± NA
ARV-473: C1D1193.5 ± 4.0425323.47 ± 36.121425.2 ± 53.143673.95 ± 19.9371022.6 ± 9.9255959.2 ± 43.348—1352.4 ± 37.377—1795.2 ± 26.921NA ± NA
ARV-473: C1D151279.2 ± 33.12243.2 ± 8.12462601.4 ± 42.0813973.7 ± 24.4435799.4 ± 34.4075084.6 ± 38.8938086.7 ± 47.1838076.6 ± 33.749NA ± NA10198 ± 40.688NA ± NA
SecondaryPart A: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant and Its Epimer ARV-473

AUClast was defined as area under the concentration-time curve from time 0 through the last quantifiable concentration (AUClast). Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Reported as:
Geometric mean · h*ng/mL
Part A: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant and Its Epimer ARV-473
h*ng/mLPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Vepdegestrant: C1D1599.09 ± 19.386957.86 ± 17.0681130.4 ± 108.472060.2 ± 25.6252782.3 ± 29.2172571.9 ± 43.2222924.4 ± 32.3123905.4 ± 38.533798.6 ± 101.635820.2 ± 31.656NA ± NA
Vepdegestrant: C1D151527.2 ± 27.1512607.6 ± 8.32212979.6 ± 45.3294831.1 ± 11.0367083.4 ± 29.4365736.7 ± 37.03314833 ± 25.6699382 ± 27.929NA ± NA12296 ± 32.053NA ± NA
ARV-473: C1D139.267 ± 23.63756.59 ± 20.6869.024 ± 165.07122.5 ± 28.646163.56 ± 38.77157.7 ± 43.521178.88 ± 47.75253.86 ± 38.75219.79 ± 95.555361.45 ± 30.093NA ± NA
ARV-473: C1D15425.26 ± 35.876770.48 ± 6.2883871.9 ± 48.3111311.2 ± 23.6771940.2 ± 34.5691618.9 ± 36.4075384.5 ± 47.7052643 ± 32.639NA ± NA3335.2 ± 40.576NA ± NA
SecondaryPart A: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant and Its Epimer ARV-473

Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Reported as:
Geometric mean · ng/mL
Part A: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant and Its Epimer ARV-473
ng/mLPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Vepdegestrant: C1D1108.88 ± 5.6696194.44 ± 33.011251.04 ± 40.887403.68 ± 21.071591.69 ± 14.076533.64 ± 52.319663.05 ± 18.043748.38 ± 34.275716.2 ± 130.531046.1 ± 31.065NA ± NA
Vepdegestrant: C1D15219.21 ± 26.659404.53 ± 7.6864478.28 ± 41.379798.83 ± 5.79711062.3 ± 27.301882.6 ± 43.1162212.5 ± 28.6041501.6 ± 26.697NA ± NA1883 ± 30.568NA ± NA
ARV-473: C1D111.032 ± 15.26919.748 ± 43.60824.888 ± 41.35539.324 ± 28.38962.344 ± 12.97558.607 ± 50.92751.931 ± 25.60976.925 ± 44.57347.44 ± 119.498.066 ± 28.697NA ± NA
ARV-473: C1D1557.645 ± 31.847108.2 ± 6.0056131.26 ± 44.089191.08 ± 18.518273.35 ± 31.598233.57 ± 36.903761.99 ± 50.623381.65 ± 31.454NA ± NA480.42 ± 41.513NA ± NA
SecondaryPart A: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant and Its Epimer ARV- 473

Cmin was defined as the minimum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
Reported as:
Geometric mean · ng/mL
Part A: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant and Its Epimer ARV- 473
ng/mLPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Vepdegestrant: C1D15125.3 ± 35.121207.19 ± 8.3176208.82 ± 54.16380.95 ± 24.591573.38 ± 44.962444.36 ± 44.2011420.8 ± 27.985757.52 ± 35.202NA ± NA1020.9 ± 44.61NA ± NA
ARV-473: C1D1548.45 ± 33.54885.191 ± 1.783483.063 ± 64.476142.73 ± 31.638210.58 ± 39.478174.72 ± 48.717561.84 ± 43.197290.01 ± 37.161NA ± NA365.46 ± 41.587NA ± NA
SecondaryPart A: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant

CL/F was defined as the apparent oral plasma clearance of vepdegestrant. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
Reported as:
Geometric mean · L/h
Part A: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant
L/hPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Part A: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant7.4 ± 25.68.19 ± 15.312.5 ± 40.18.75 ± 12.99.36 ± 31.812.7 ± 37.811.3 ± 28.813.9 ± 26.6NA ± NA14.5 ± 35.5NA ± NA
SecondaryPart A: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant and Its Epimer ARV- 473

Tmax was defined as the time of maximum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (median) was not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Reported as:
Median · hours
Part A: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant and Its Epimer ARV- 473
hoursPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Vepdegestrant: C1D14.02 (4.00 to 5.87)6.02 (4.00 to 6.10)5.75 (2.22 to 26.05)5.92 (4.03 to 7.82)5.98 (4.03 to 7.82)5.82 (4.00 to 7.75)6.86 (2.00 to 7.87)5.83 (3.98 to 7.78)4.13 (3.93 to 5.82)4.94 (0.95 to 7.95)NA (5.75 to 5.75)
Vepdegestrant: C1D154.08 (3.92 to 6.00)4.15 (3.95 to 6.00)4.25 (1.87 to 7.98)5.92 (3.93 to 7.78)5.03 (2.08 to 5.97)4.05 (3.83 to 7.80)5.97 (1.97 to 7.92)5.77 (3.92 to 8.08)NA (4.10 to 5.95)5.92 (3.83 to 7.78)NA (5.95 to 5.95)
ARV-473: C1D124.00 (24.00 to 24.00)24.00 (24.00 to 24.00)24.00 (5.75 to 26.05)24.00 (7.67 to 24.00)24.00 (24.00 to 24.00)24.00 (24.00 to 24.92)7.78 (4.00 to 8.12)24.00 (24.00 to 24.00)7.80 (5.85 to 7.85)24.00 (6.05 to 24.00)NA (24.00 to 24.00)
ARV-473: C1D156.03 (3.92 to 7.75)2.07 (1.02 to 5.88)5.97 (0.00 to 7.98)6.00 (3.92 to 7.78)5.88 (3.92 to 7.75)5.75 (1.03 to 7.85)4.05 (0.98 to 7.92)6.03 (1.98 to 8.75)NA (5.88 to 5.95)6.00 (3.83 to 7.80)NA (7.78 to 7.78)
SecondaryPart A: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant and Its Epimer ARV- 473

Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Reported as:
Geometric mean · ratio
Part A: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant and Its Epimer ARV- 473
ratioPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Vepdegestrant2.36 ± 21.42.47 ± 18.82.19 ± 22.52.17 ± 18.62.01 ± 23.11.66 ± 49.1—2.13 ± 28.5—2.04 ± 39.6NA ± NA
ARV-4736.61 ± 28.86.93 ± 27.56.14 ± 30.95.9 ± 30.45.7 ± 37.35.19 ± 49.7—5.97 ± 33.6—5.66 ± 48.5NA ± NA
SecondaryPart A: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant and Its Epimer ARV- 473

Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Reported as:
Geometric mean · ratio
Part A: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant and Its Epimer ARV- 473
ratioPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Vepdegestrant2.01 ± 25.92.08 ± 24.91.99 ± 27.91.98 ± 16.41.78 ± 23.71.57 ± 56.63.3 ± 20.32.01 ± 23.1NA ± NA1.76 ± 35.6NA ± NA
ARV-4735.23 ± 22.65.48 ± 40.65.15 ± 31.84.86 ± 28.94.49 ± 28.83.96 ± 53.813.7 ± 52.64.96 ± 37.9NA ± NA4.93 ± 50.4NA ± NA
SecondaryPart A: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) of Vepdegestrant and Its Epimer ARV-473

Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Reported as:
Mean · hour
Part A: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) of Vepdegestrant and Its Epimer ARV-473
hourPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Vepdegestrant30.8 ± 8.1732.5 ± 7.5728 ± 8.5627.4 ± 7.524.8 ± 7.5823 ± 13.4—27.5 ± 10.8—26.8 ± 14.6NA ± NA
ARV-473104 ± 29.9110 ± 30.698.3 ± 35.993.4 ± 32.291 ± 31.586 ± 42.9—95.6 ± 32.8—94.9 ± 47.8NA ± NA
SecondaryPart A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for Cmax (MRCmax).

The epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Reported as:
Geometric mean · ratio
Part A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for Cmax (MRCmax).
ratioPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
C1D10.101 ± 17.40.102 ± 10.90.0991 ± 24.80.0974 ± 330.105 ± 16.60.11 ± 20.40.0783 ± 27.30.103 ± 29.60.0662 ± 6.850.0937 ± 20NA ± NA
C1D150.263 ± 9.260.267 ± 7.870.274 ± 21.50.239 ± 19.80.257 ± 17.20.265 ± 230.344 ± 30.90.254 ± 26.9NA ± NA0.255 ± 26NA ± NA
SecondaryPart A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for AUCtau (MRAUCtau)

The epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Reported as:
Geometric mean · ratio
Part A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for AUCtau (MRAUCtau)
ratioPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 250 mgPart A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 400 mg/300 mgPart A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
C1D10.113 ± 3.420.109 ± 3.130.113 ± 12.90.107 ± 13.90.107 ± 10.90.105 ± 16.8—0.111 ± 16.1—0.107 ± 7.79NA ± NA
C1D150.316 ± 9.830.306 ± 7.590.325 ± 210.29 ± 17.30.302 ± 13.90.322 ± 14.70.367 ± 27.80.311 ± 15.2NA ± NA0.295 ± 18.5NA ± NA
SecondaryPart A: Overall Response Rate (ORR) by Investigator Per RECIST v1.1

ORR was defined as the percentage of participants with best overall response (BOR) of CR and PR as per Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1). BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.

Time frame:
From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
Reported as:
Number · percentage of participants
Part A: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
percentage of participantsPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Part A: Overall Response Rate (ORR) by Investigator Per RECIST v1.10 (0.0 to 70.8)0 (0.0 to 84.2)25.0 (5.5 to 57.2)20.0 (0.5 to 71.6)0 (0.0 to 45.9)14.3 (0.4 to 57.9)18.2 (2.3 to 51.8)5.6 (0.1 to 27.3)0 (0.0 to 97.5)
SecondaryPart A: Clinical Benefit Rate (CBR)

CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.

Time frame:
From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
Reported as:
Number · percentage of participants
Part A: Clinical Benefit Rate (CBR)
percentage of participantsPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Part A: Clinical Benefit Rate (CBR)33.3 (0.8 to 90.6)33.3 (0.8 to 90.6)42.9 (17.7 to 71.1)71.4 (29.0 to 96.3)14.3 (0.4 to 57.9)12.5 (0.3 to 52.7)40.0 (16.3 to 67.7)31.8 (13.9 to 54.9)50.0 (6.8 to 93.2)
SecondaryPart A: Disease Control Rate (DCR)

DCR: percentage of participants with CR, PR or SD. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. DCR was based on confirmed responses. Confirmed responses were at least 4 weeks after the criteria for response were first met.

Time frame:
From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
Reported as:
Number · percentage of participants
Part A: Disease Control Rate (DCR)
percentage of participantsPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Part A: Disease Control Rate (DCR)33.3 (0.8 to 90.6)33.3 (0.8 to 90.6)61.5 (31.6 to 86.1)85.7 (42.1 to 99.6)50.0 (11.8 to 88.2)25.0 (3.2 to 65.1)73.3 (44.9 to 92.2)47.4 (24.4 to 71.1)50.0 (6.8 to 93.2)
SecondaryPart A: Progression-Free Survival (PFS) Per RECIST v1.1

PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Kaplan-Meier (KM) estimate was used for analysis.

Time frame:
From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
Reported as:
Median · months
Part A: Progression-Free Survival (PFS) Per RECIST v1.1
monthsPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Part A: Progression-Free Survival (PFS) Per RECIST v1.1NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPart A: Duration of Response

DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

Time frame:
From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 4 years and 6 months)
Reported as:
Median · months
Part A: Duration of Response
monthsPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Part A: Duration of Response——NA (NA to NA)NA (NA to NA)—NA (NA to NA)NA (NA to NA)NA (NA to NA)—
SecondaryPart B: Overall Response Rate (ORR) by Investigator Per RECIST v1.1

ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version \[v\] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.

Time frame:
From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
Reported as:
Number · percentage of participants
Part B: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
percentage of participantsPart B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)
Part B: Overall Response Rate (ORR) by Investigator Per RECIST v1.18.3 (1.0 to 27.0)14.3 (3.0 to 36.3)
SecondaryPart B: Progression-Free Survival (PFS) Per RECIST v1.1

PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

Time frame:
From start of study treatment up to progressive disease or death (up to approximately 2 years and 11 months)
Reported as:
Median · months
Part B: Progression-Free Survival (PFS) Per RECIST v1.1
monthsPart B - Phase 2: Vepdegestrant 200 mg (Cohort Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Cohort Expansion)
Part B: Progression-Free Survival (PFS) Per RECIST v1.13.5 (1.8 to 7.8)5.4 (1.9 to 8.8)
SecondaryPart B: Duration of Response

DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

Time frame:
From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 2 years and 11 months)
Reported as:
Median · months
Part B: Duration of Response
monthsPart B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)
Part B: Duration of Response10.4 (3.7 to NA)7.6 (5.7 to NA)
SecondaryPart B: Overall Survival

OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis.

Time frame:
From start of study treatment up to death (up to approximately 2 years and 11 months)
Reported as:
Median · months
Part B: Overall Survival
monthsPart B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)
Part B: Overall SurvivalNA (27.6 to NA)NA (19.7 to NA)
SecondaryPart B: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
From start of study treatment up to 30 days after end of study treatment (up to approximately 2 years and 11 months)
Reported as:
Count of participants · Participants
Part B: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs
ParticipantsPart B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)
TEAEs3234
Serious TEAEs65
Treatment-Related TEAEs3027
SecondaryPart B: Pre-dose Concentrations of Vepdegestrant and Its Epimer ARV-473

Pre-dose Plasma concentrations of vepdegestrant and ARV-473 was reported. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Predose on C1D15 and C1D28 to C26D28
Reported as:
Mean · ng/mL
Part B: Pre-dose Concentrations of Vepdegestrant and Its Epimer ARV-473
ng/mLPart B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)
Vepdegestrant: C1D15603.621 ± 422.4487956.692 ± 403.4008
Vepdegestrant: C1D28637.783 ± 323.53151030.000 ± 590.7248
Vepdegestrant: C2D28527.143 ± 273.8017839.313 ± 405.5787
Vepdegestrant: C3D28524.067 ± 236.7164981.538 ± 457.8516
Vepdegestrant: C4D28525.727 ± 268.2164918.532 ± 464.2570
Vepdegestrant: C5D28534.364 ± 245.32321148.100 ± 690.3299
Vepdegestrant: C6D28501.000 ± 302.0592984.000 ± 417.0430
Vepdegestrant: C7D28444.444 ± 179.8285957.333 ± 542.0904
Vepdegestrant: C8D28473.036 ± 282.8287895.000 ± 383.0244
Vepdegestrant: C9D28387.500 ± 129.39221043.250 ± 288.6328
Vepdegestrant: C10D28436.500 ± 133.72231216.400 ± 638.9502
Vepdegestrant: C11D28404.000 ± 210.02861128.400 ± 427.0162
Vepdegestrant: C12D28410.000 ± NA1175.500 ± 445.2277
Vepdegestrant: C13D28504.000 ± 224.3056974.000 ± 588.0034
Vepdegestrant: C14D28510.000 ± 222.08331134.000 ± 341.2096
Vepdegestrant: C15D28423.250 ± 244.6853940.500 ± 547.7283
Vepdegestrant: C16D28451.750 ± 184.97091111.500 ± 536.1129
Vepdegestrant: C17D28488.500 ± 162.43461003.500 ± 601.5538
Vepdegestrant: C18D28477.667 ± 355.35941163.500 ± NA
Vepdegestrant: C19D28303.500 ± NA1226.500 ± NA
Vepdegestrant: C20D28468.000 ± NA382.000 ± NA
Vepdegestrant: C21D28383.500 ± NA519.000 ± NA
Vepdegestrant: C22D28666.000 ± NA470.000 ± NA
Vepdegestrant: C23D28446.000 ± NA408.000 ± NA
Vepdegestrant: C24D28—536.000 ± NA
Vepdegestrant: C25D28—463.000 ± NA
Vepdegestrant: C26D28—549.000 ± NA
ARV-473: C1D15245.43 ± 162.212361.58 ± 166.885
ARV-473: C1D28272.78 ± 151.084382.32 ± 242.746
ARV-473: C2D28219.26 ± 118.820311.88 ± 144.295
ARV-473: C3D28206.77 ± 106.138349.85 ± 149.663
ARV-473: C4D28187.34 ± 97.274363.97 ± 184.902
ARV-473: C5D28199.14 ± 86.539410.60 ± 200.839
ARV-473: C6D28175.32 ± 93.520348.38 ± 142.711
ARV-473: C7D28180.06 ± 82.097348.44 ± 172.105
ARV-473: C8D28184.99 ± 112.859332.43 ± 153.503
ARV-473: C9D28143.48 ± 63.649309.50 ± 109.061
ARV-473: C10D28175.25 ± 40.599401.60 ± 171.221
ARV-473: C11D28147.57 ± 67.260376.20 ± 131.665
ARV-473: C12D28158.50 ± NA416.75 ± 169.567
ARV-473: C13D28178.83 ± 76.819341.00 ± 177.085
ARV-473: C14D28185.00 ± 75.439437.00 ± 103.766
ARV-473: C15D28153.35 ± 64.547337.75 ± 168.300
ARV-473: C16D28175.25 ± 61.711392.50 ± 159.475
ARV-473: C17D28172.00 ± 78.456364.00 ± 187.729
ARV-473: C18D28182.67 ± 143.309393.50 ± NA
ARV-473: C19D28125.50 ± NA406.00 ± NA
ARV-473: C20D28189.00 ± NA165.00 ± NA
ARV-473: C21D28181.50 ± NA222.00 ± NA
ARV-473: C22D28263.00 ± NA203.00 ± NA
ARV-473: C23D28181.00 ± NA169.00 ± NA
ARV-473: C24D28—214.00 ± NA
ARV-473: C25D28—221.00 ± NA
ARV-473: C26D28—219.00 ± NA
SecondaryPart C: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant \& ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant \& ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for drug-drug interaction (DDI) evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
Reported as:
Geometric mean · h*ng/mL
Part C: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
h*ng/mLPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Vepdegestrant: C1D1NA ± NA7779.7 ± 42.14614900 ± 27.6516133 ± 29.712—
Vepdegestrant: C1D15NA ± NA18416 ± 46.65821522 ± 8.069833367 ± 37.641—
Vepdegestrant: C1D21/C2D15————14216 ± 36.696
ARV-473: C1D1NA ± NA931.33 ± 41.9331402.6 ± 35.9531833.1 ± 28.576—
ARV-473: C1D15NA ± NA6905.6 ± 57.5016598.7 ± 10.19511893 ± 44.365—
ARV-473: C1D21/C2D15————5186.3 ± 49.384
Palbociclib: C1D1—907.67 ± 31.759NA ± NA819.86 ± 51.572—
Palbociclib: C1D8————1742.9 ± 33.966
Palbociclib: C1D15—2902.9 ± 45.7442571.1 ± 16.8212992.1 ± 39.59—
Palbociclib: C1D21/C2D15————1804.9 ± 42.571
SecondaryPart C: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
Reported as:
Geometric mean · h*ng/mL
Part C: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
h*ng/mLPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Vepdegestrant: C1D1NA ± NA2351.2 ± 60.6583864.9 ± 25.6294754.7 ± 46.211—
Vepdegestrant: C1D15NA ± NA6493.1 ± 45.9818274.6 ± 20.53911378 ± 43.389—
Vepdegestrant: C1D21/C2D15————4940.9 ± 38.306
ARV-473: C1D1NA ± NA165.52 ± 64.373221.05 ± 28.37316.86 ± 52.866—
ARV-473: C1D15NA ± NA2273.9 ± 53.0452252 ± 14.9833730.6 ± 47.654—
ARV-473: C1D21/C2D15————1693.5 ± 49.814
Palbociclib: C1D1—253.98 ± 63.902NA ± NA219.28 ± 133.03—
Palbociclib: C1D8————620.4 ± 36.956
Palbociclib: C1D15—987.34 ± 45.683848.43 ± 21.093929.8 ± 59.414—
Palbociclib: C1D21/C2D15————597.88 ± 42.112
SecondaryPart C: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
Reported as:
Geometric mean · ng/mL
Part C: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
ng/mLPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Vepdegestrant: C1D1NA ± NA506.3 ± 40.74972.26 ± 22.31980.86 ± 36.161—
Vepdegestrant: C1D15NA ± NA1046.4 ± 44.6321347.8 ± 14.1331795.5 ± 36.661—
Vepdegestrant: C1D21/C2D15————790.6 ± 35.141
ARV-473: C1D1NA ± NA56.054 ± 35.14687.066 ± 24.59105.15 ± 32.657—
ARV-473: C1D15NA ± NA336.12 ± 55.493334.13 ± 19.859576.82 ± 48.933—
ARV-473: C1D21/C2D15————238.23 ± 47.27
Palbociclib: C1D1—59.851 ± 32.502NA ± NA59.453 ± 56.309—
Palbociclib: C1D8————98.171 ± 39.202
Palbociclib: C1D15—153.42 ± 45.26127.46 ± 26.185155.53 ± 39.057—
Palbociclib: C1D21/C2D15————95.999 ± 32.041
SecondaryPart C: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

Cmin was defined as the minimum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
Reported as:
Geometric mean · ng/mL
Part C: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
ng/mLPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Vepdegestrant: C1D15NA ± NA472.59 ± 81.959637.02 ± 7.93821102.3 ± 42.598—
Vepdegestrant: C1D21/C2D15————420.7 ± 43.572
ARV-473: C1D15NA ± NA199.89 ± 88.088245.71 ± 8.7464437.29 ± 42.344—
ARV-473: C1D21/C2D15————189.86 ± 51.056
Palbociclib: C1D8————51.963 ± 39.374
Palbociclib: C1D15—91.821 ± 48.47488.771 ± 10.07696.593 ± 46.645—
Palbociclib: C1D21/C2D15————NA ± NA
SecondaryPart C: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant and Palbociclib

As planned for Part C, PK data of vepdegestrant and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
Reported as:
Geometric mean · L/h
Part C: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant and Palbociclib
L/hPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Vepdegestrant: C1D15NA ± NA10.9 ± 46.718.6 ± 8.0715 ± 37.6—
Vepdegestrant: C1D21/C2D15————14.1 ± 36.7
Palbociclib: C1D8————56.2 ± 35
Palbociclib: C1D15—43.1 ± 45.748.6 ± 16.841.8 ± 39.6—
Palbociclib: C1D21/C2D15————55.4 ± 42.6
SecondaryPart C: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

Tmax was defined as the time of maximum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
Reported as:
Median · hour
Part C: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
hourPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Vepdegestrant: C1D1NA (6.00 to 6.02)5.83 (1.92 to 23.92)7.78 (6.07 to 7.90)5.94 (1.85 to 7.80)—
Vepdegestrant: C1D15NA (4.03 to 4.07)4.08 (2.00 to 8.08)5.92 (3.98 to 6.03)4.09 (2.03 to 7.75)—
Vepdegestrant: C1D21/C2D15————5.96 (3.83 to 7.78)
ARV-473: C1D1NA (21.83 to 23.10)23.72 (5.83 to 28.83)23.98 (21.13 to 25.15)23.65 (7.78 to 27.48)—
ARV-473: C1D15NA (4.03 to 8.03)7.77 (1.03 to 8.08)5.92 (3.98 to 6.03)4.14 (0.00 to 8.00)—
ARV-473: C1D21/C2D15————5.91 (3.83 to 7.87)
Palbociclib: C1D1—6.10 (1.95 to 8.13)NA (6.07 to 7.78)5.98 (1.83 to 27.48)—
Palbociclib: C1D8————5.96 (1.00 to 7.92)
Palbociclib: C1D15—5.93 (0.00 to 8.08)5.92 (2.03 to 6.03)5.03 (0.00 to 7.92)—
Palbociclib: C1D21/C2D15————6.00 (0.93 to 7.78)
SecondaryPart C: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
Reported as:
Geometric mean · ratio
Part C: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
ratioPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
VepdegestrantNA ± NA2.29 ± 37.21.44 ± 27.22.05 ± 28.5—
ARV-473NA ± NA7.2 ± 40.24.7 ± 37.36.43 ± 37.2—
Palbociclib—2.92 ± 16NA ± NA3.47 ± 41.7—
SecondaryPart C: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
Reported as:
Geometric mean · ratio
Part C: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
ratioPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
VepdegestrantNA ± NA1.96 ± 40.81.39 ± 14.51.79 ± 23.6—
ARV-473NA ± NA5.86 ± 323.84 ± 31.85.39 ± 39.5—
Palbociclib—2.44 ± 24.4NA ± NA2.74 ± 48.2—
SecondaryPart C: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) (Effective T1/2) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib

Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12, 24 hours post dose on C1D15 for arms with palbociclib 125 mg (each cycle is of 28 days)
Reported as:
Mean · hours
Part C: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) (Effective T1/2) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
hoursPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
VepdegestrantNA ± NA31.2 ± 15.314.5 ± 7.5925.9 ± 9.91—
ARV-473NA ± NA120 ± 48.373.2 ± 31.6104 ± 37—
Palbociclib—40.2 ± 7.65NA ± NA53.7 ± 28.8—
SecondaryPart C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for Cmax (MRCmax)

Epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant, ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1/C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21/C2D15. As per protocol, in 100 mg palbociclib administered arm, intensive PK sample collection not done on C1D21 was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.
Reported as:
Geometric mean · ratio
Part C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for Cmax (MRCmax)
ratioPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
C1D1NA ± NA0.111 ± 33.30.0896 ± 3.390.107 ± 25.4—
C1D15NA ± NA0.321 ± 25.90.248 ± 13.50.321 ± 30.3—
C1D21/C2D15————0.301 ± 22.1
SecondaryPart C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for AUCtau (MRAUCtau)

Epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.
Reported as:
Geometric mean · ratio
Part C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for AUCtau (MRAUCtau)
ratioPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
C1D1NA ± NA0.12 ± 17.30.0941 ± 9.210.114 ± 12.1—
C1D15NA ± NA0.375 ± 22.10.307 ± 2.120.356 ± 15.2—
C1D21/C2D15————0.365 ± 19.2
SecondaryPart C: Overall Response Rate (ORR) by Investigator Per RECIST v1.1

ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version \[v\] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.

Time frame:
From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)
Reported as:
Number · percentage of participants
Part C: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
percentage of participantsPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Part C: Overall Response Rate (ORR) by Investigator Per RECIST v1.10 (0.0 to 97.5)53.3 (26.6 to 78.7)0 (0.0 to 97.5)35.7 (12.8 to 64.9)14.3 (0.4 to 57.9)
SecondaryPart C: Clinical Benefit Rate (CBR)

CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.

Time frame:
From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)
Reported as:
Number · percentage of participants
Part C: Clinical Benefit Rate (CBR)
percentage of participantsPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Part C: Clinical Benefit Rate (CBR)100 (15.8 to 100.0)66.7 (43.0 to 85.4)100 (29.2 to 100)50.0 (27.2 to 72.8)29.4 (10.3 to 56.0)
SecondaryPart C: Progression-Free Survival (PFS) Per RECIST v1.1

PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

Time frame:
From start of study treatment up to progressive disease or death (up to approximately 3 years and 9 months)
Reported as:
Median · months
Part C: Progression-Free Survival (PFS) Per RECIST v1.1
monthsPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Part C: Progression-Free Survival (PFS) Per RECIST v1.111.1 (11.1 to NA)13.9 (8.0 to 19.3)NA (23.1 to NA)5.6 (3.6 to 13.7)3.7 (2.1 to 8.5)
SecondaryPart C: Overall Survival

OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis.

Time frame:
From start of study treatment up to death (up to approximately 3 years and 9 months)
Reported as:
Median · months
Part C: Overall Survival
monthsPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Part C: Overall SurvivalNA (NA to NA)28.4 (26.9 to NA)NA (28.3 to NA)23.4 (8.3 to NA)NA (6.8 to NA)
SecondaryPart C: Duration of Response

DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.

Time frame:
From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 3 years and 9 months)
Reported as:
Median · months
Part C: Duration of Response
monthsPart C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Part C: Duration of Response—14.6 (4.5 to 15.9)—13.8 (9.5 to NA)6.6 (NA to NA)

Adverse events

Collected over AEs: From start of study treatment up to 30 days after EOT For Part A: Up to approx. 4 years and 6 months For Part B: Up to approx. 2 years and 11 months For Part C: Up to approx. 3 years and 9 months All-cause mortality: Part A: From enrollment up to 30 days after EOT For Part A: Up to approx. 4 years and 6 months For Part B Up to approx. 2 years and 11 months For Part C: Up to approx. 3 years and 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)4/15 (26.7%)3/14 (21.4%)14/14 (100%)
Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)5/7 (71.4%)0/7 (0%)7/7 (100%)
Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)5/7 (71.4%)0/7 (0%)7/7 (100%)
Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)4/8 (50%)1/8 (12.5%)8/8 (100%)
Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)7/15 (46.7%)2/15 (13.3%)15/15 (100%)
Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)15/22 (68.2%)2/22 (9.1%)21/22 (95.5%)
Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)2/4 (50%)1/4 (25%)3/4 (75%)
Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)12/35 (34.3%)6/35 (17.1%)32/35 (91.4%)
Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)14/36 (38.9%)5/36 (13.9%)34/36 (94.4%)
Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)0/2 (0%)1/2 (50%)2/2 (100%)
Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)6/21 (28.6%)8/21 (38.1%)21/21 (100%)
Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)13/21 (61.9%)4/20 (20%)20/20 (100%)
Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)4/17 (23.5%)6/17 (35.3%)17/17 (100%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Corona virus infectionInfections and infestations0/30/30/140/70/70/80/150/220/40/350/361/20/210/30/200/17
Procedural painInjury, poisoning and procedural complications1/30/30/140/70/70/80/150/220/40/350/360/20/210/30/200/17
Spinal cord compressionNervous system disorders0/31/30/140/70/70/80/150/220/40/351/360/20/210/31/200/17
Gastroenteritis viralInfections and infestations0/30/30/140/70/70/80/150/220/40/350/360/20/211/30/200/17
Electrocardiogram QT prolongedInvestigations0/30/30/140/70/70/80/150/221/40/350/360/20/210/30/200/17
ColitisGastrointestinal disorders0/30/30/140/70/71/80/150/220/40/350/360/20/210/30/200/17
StomatitisGastrointestinal disorders0/30/30/140/70/71/80/150/220/40/350/360/20/210/30/200/17
Neutrophil count decreasedInvestigations0/30/30/140/70/71/80/150/220/40/350/360/20/210/30/200/17
AscitesGastrointestinal disorders0/30/30/140/70/70/80/150/220/40/350/360/20/210/30/202/17
DyspnoeaRespiratory, thoracic and mediastinal disorders0/30/30/140/70/70/80/150/220/40/350/360/22/210/30/201/17
Most frequent other events
Showing 10 of 234
Most frequent other events
EventPart A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
NeutropeniaBlood and lymphatic system disorders0/30/30/141/71/70/80/150/220/40/350/362/27/210/38/202/17
FatigueGeneral disorders0/31/36/141/72/74/86/1513/222/418/3516/362/214/211/313/208/17
Corona virus infectionInfections and infestations0/30/31/140/70/70/80/151/220/42/352/362/22/210/32/201/17
Neutrophil count decreasedInvestigations0/30/31/140/70/70/81/152/221/45/352/361/214/213/314/2011/17
AnaemiaBlood and lymphatic system disorders0/30/31/140/70/72/82/150/221/44/356/360/29/212/38/203/17
ConstipationGastrointestinal disorders0/32/35/142/71/72/85/1511/221/45/359/360/27/210/36/204/17
DiarrhoeaGastrointestinal disorders0/30/36/140/70/71/84/153/221/43/353/361/25/212/34/203/17
NauseaGastrointestinal disorders0/32/33/142/72/73/85/159/222/49/3512/361/24/211/39/205/17
Platelet count decreasedInvestigations0/30/30/140/71/70/80/151/220/40/350/360/211/212/310/204/17
White blood cell count decreasedInvestigations0/30/32/140/70/70/81/151/221/43/352/360/26/212/36/202/17

Baseline characteristics

The All-Treated Analysis Set consisted of all enrolled participants who had received any amount of vepdegestrant dose (partial or complete) for monotherapy cohorts or any study drug for combination therapy cohorts.

Age, Continuous
Age, Continuous(years)Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)Total
Mean69.0 ± 2.6567.3 ± 2.8962.1 ± 11.8063.1 ± 11.0462.7 ± 9.9661.5 ± 11.6664.3 ± 8.1958.9 ± 11.4663.5 ± 9.0460.1 ± 10.4659.6 ± 9.5659.5 ± 4.9563.8 ± 11.5052.3 ± 10.9758.3 ± 10.1562.4 ± 12.1261.07 ± 10.44
Sex: Female, Male
Sex: Female, Male(Participants)Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)Total
Female331377815224343522032015211
Male00100000011010026
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)Total
Hispanic or Latino002000300230002012
Not Hispanic or Latino331276812224333022131717200
Unknown or Not Reported00001000003000105
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)Total
American Indian or Alaska Native00000000000000000
Asian00001100012020018
Native Hawaiian or Other Pacific Islander00000000010000001
Black or African American00301000001000106
White331175714194303121931716191
More than one race00000000000000000
Unknown or Not Reported000000130320002011
08

Study locations

16 sites
  • Clinical Trial Site
    Palo Alto, California 94304, United States
  • Clinical Trial Site
    San Francisco, California 94158, United States
  • Clinical Trial Site
    Santa Monica, California 90404, United States
  • Clinical Trial Site
    Norwalk, Connecticut 06856, United States
  • Clinical Trial Site
    Fort Myers, Florida 33901, United States
  • Clinical Trial Site
    Tampa, Florida 33612, United States
  • Clinical Trial Site
    Chicago, Illinois 60637, United States
  • Clinical Trial Site
    Boston, Massachusetts 02114, United States
  • Clinical Trial Site
    Boston, Massachusetts 02215, United States
  • Clinical Trial Site
    Ann Arbor, Michigan 48109, United States
  • Clinical Trial Site
    St Louis, Missouri 63110, United States
  • Clinical Trial Site
    East Brunswick, New Jersey 08816, United States
  • Clinical Trial Site
    The Bronx, New York 10461, United States
  • Clinical Trial Site
    Charlotte, North Carolina 28204, United States
  • Clinical Trial Site
    Nashville, Tennessee 37203, United States
  • Clinical Trial Site
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Sep 2024, 59 months.

Results were first posted in Sep 2026, 2 years after primary completion. A results delay was requested in Sep 2025.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 59 months is close to that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

Start moved once since we started tracking on Sep 25, 2026: Aug 2019 → Sep 2019, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2019
First posted
Aug 28, 2019
StartActual
Sep 22, 2019was Aug 2019
Primary completionActual
Sep 13, 2024
CompletionActual
Mar 5, 2026
Results delay requested
Sep 8, 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Start date
Aug 5, 2019→Sep 22, 2019
Sep 29, 2026
Enrollment
217→219
Sep 29, 2026
Eligibility
10 inclusion criteria edited, 2 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatientsParticipants at least 18 years of age at the time of signing the informed consent.
  • EditedPatientsParticipants must have histologically or cytologically confirmed ER+ and HER2- advanced breast cancer for which standard curative therapy is no longer effective or does not exist.
  • EditedPatientsParticipants must have measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST criteria) (version1.1), with radiologic tumor assessments performed within 28 days of the first dose of therapy.
  • EditedPatientsParticipants must be willing to undergo a core biopsy of accessible tumor within 4 weeks prior to the initiation of study treatment and a follow-up biopsy on treatment for ER immunohistochemistry (IHC) testing and pharmacodynamics (PD) studies. (Patients without accessible tumor tissue may be eligible after discussion with the Medical Monitor.)
  • Edited- PatientsParticipants must have received at least 2 prior endocrine regimens in any setting (neoadjuvant, adjuvant or advanced/metastatic) a CDK4/6 inhibitor and up to 3 prior regimens of cytotoxic chemotherapy in the locally advanced or metastatic setting.
  • EditedPatientsParticipants must have received at least 1 prior endocrine regimen for a minimum of 6 months in the locally advanced or metastatic setting; if more than 1 prior endocrine regimen has been administered, only one of the regimens must have been administered for a minimum of 6 months in the locally advanced or metastatic setting
  • EditedPatientsParticipants must have received a CDK4/6 inhibitor
  • EditedPatientsParticipants must have received up to 1 prior regimen of cytotoxic chemotherapy in the locally advanced or metastatic setting
  • RemovedWomen must be postmenopausal due to surgical or natural menopause.
  • EditedPatientsParticipants must have received at least one prior endocrine regimen.
  • EditedPatientsParticipants must have received no more than two prior chemotherapy regimens for advanced disease.
  • RemovedWomen must be postmenopausal due to surgical or natural menopause.
Exclusion criteria
  • EditedPatientsParticipants with known symptomatic brain metastases requiring steroids (above physiologic replacement doses). Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to first dose of study drug, have discontinued high-dose corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable as judged by the Investigator.
Sep 29, 2026
Interventions
Changed ARV-471→Vepdegestrant; ARV-471 in combination with palbociclib (IBRANCE®)→Palbociclib. Added Drug: Vepdegestrant. Arms added: Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)·Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)·Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)·Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)·Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)·and 11 more
All 16

Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) · Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) · Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)

; arms removed: ARV-471·ARV-471 and palbociclib (IBRANCE®)
Sep 29, 2026
Primary outcomes
1 edited, 5 added, 6 removed
What changed in the outcomes
  • EditedPart A: IncidenceNumber of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of ARV-471TreatmentTime frame: 28 Days → Baseline (Day 1) up to C1D28
  • AddedPart A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)
  • AddedPart B: Clinical Benefit Rate (CBR)Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
  • AddedPart C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of TreatmentTime frame: Baseline (Day 1) up to C1D28
  • AddedPart C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)
  • AddedPart C: Maximum Tolerated Dose (MTD)Time frame: Baseline (Day 1) up to C1D28
  • RemovedPart A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-471Time frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration
  • RemovedPart A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-471Time frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration
  • RemovedPart B: Assessment of anti-tumor activity of ARV-471Time frame: through study completion, up to approximately 2 years
  • RemovedPart C: Incidence of Dose Limiting Toxicities of combination ARV-471 + palbociclibTime frame: 28 Days
  • RemovedPart C: Number of Patients with Adverse Events as a measure of safety and tolerability of combination ARV-471 + palbociclibTime frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration
  • RemovedPart C: Incidence of laboratory abnormalities as a measure of safety and tolerability of combination ARV-471 + palbociclibTime frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration
Sep 29, 2026
Documents
Secondary outcomes
4 edited, 26 added, 27 more
What changed in the outcomes
  • EditedPart A: AssessmentArea Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of pharmacokinetic (PK) parameter area under the concentrationVepdegestrant and Its Epimer ARV-time curve (AUC).473Time frame: At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of ARV-471 → Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1.
  • EditedPart B: Evaluation of PlasmaPre-dose Concentrations of Vepdegestrant and Its Epimer ARV-471473Time frame: At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products] → Predose on C1D15 and C1D28 to C26D28
  • EditedPart B: EvaluationDuration of Safety and TolerabilityResponseTime frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration → From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 2 years and 11 months)
  • EditedPart C:Assessment Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of pharmacokinetic parameter area under the concentration-time curve (AUC)Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products → Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
  • AddedPart A: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant and Its Epimer ARV-473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
  • AddedPart A: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant and Its Epimer ARV-473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
  • AddedPart A: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant and Its Epimer ARV- 473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
  • AddedPart A: Apparent Oral Plasma Clearance (CL/F) of VepdegestrantTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
  • AddedPart A: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant and Its Epimer ARV- 473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
  • AddedPart A: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant and Its Epimer ARV- 473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
  • AddedPart A: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant and Its Epimer ARV- 473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
  • AddedPart A: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) of Vepdegestrant and Its Epimer ARV-473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
  • AddedPart A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for Cmax (MRCmax).Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
  • AddedPart A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for AUCtau (MRAUCtau)Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
  • AddedPart A: Overall Response Rate (ORR) by Investigator Per RECIST v1.1Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
  • AddedPart A: Clinical Benefit Rate (CBR)Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
  • AddedPart A: Disease Control Rate (DCR)Time frame: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
  • AddedPart A: Progression-Free Survival (PFS) Per RECIST v1.1Time frame: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
  • AddedPart A: Duration of ResponseTime frame: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 4 years and 6 months)
  • AddedPart B: Overall Response Rate (ORR) by Investigator Per RECIST v1.1Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
  • AddedPart B: Progression-Free Survival (PFS) Per RECIST v1.1Time frame: From start of study treatment up to progressive disease or death (up to approximately 2 years and 11 months)
  • AddedPart B: Overall SurvivalTime frame: From start of study treatment up to death (up to approximately 2 years and 11 months)
  • AddedPart B: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 2 years and 11 months)
  • AddedPart C: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
  • AddedPart C: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
  • AddedPart C: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
  • AddedPart C: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
  • AddedPart C: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
  • AddedPart C: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
  • AddedPart C: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
  • …and 27 more, on the record history on ClinicalTrials.gov ↗
Sep 29, 2026
Title
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in PatientsParticipants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Start date Aug 5, 2019→Sep 22, 2019
    Enrollment 217→219
    Eligibility 10 inclusion criteria edited, 2 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatientsParticipants at least 18 years of age at the time of signing the informed consent.
    • EditedPatientsParticipants must have histologically or cytologically confirmed ER+ and HER2- advanced breast cancer for which standard curative therapy is no longer effective or does not exist.
    • EditedPatientsParticipants must have measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST criteria) (version1.1), with radiologic tumor assessments performed within 28 days of the first dose of therapy.
    • EditedPatientsParticipants must be willing to undergo a core biopsy of accessible tumor within 4 weeks prior to the initiation of study treatment and a follow-up biopsy on treatment for ER immunohistochemistry (IHC) testing and pharmacodynamics (PD) studies. (Patients without accessible tumor tissue may be eligible after discussion with the Medical Monitor.)
    • Edited- PatientsParticipants must have received at least 2 prior endocrine regimens in any setting (neoadjuvant, adjuvant or advanced/metastatic) a CDK4/6 inhibitor and up to 3 prior regimens of cytotoxic chemotherapy in the locally advanced or metastatic setting.
    • EditedPatientsParticipants must have received at least 1 prior endocrine regimen for a minimum of 6 months in the locally advanced or metastatic setting; if more than 1 prior endocrine regimen has been administered, only one of the regimens must have been administered for a minimum of 6 months in the locally advanced or metastatic setting
    • EditedPatientsParticipants must have received a CDK4/6 inhibitor
    • EditedPatientsParticipants must have received up to 1 prior regimen of cytotoxic chemotherapy in the locally advanced or metastatic setting
    • RemovedWomen must be postmenopausal due to surgical or natural menopause.
    • EditedPatientsParticipants must have received at least one prior endocrine regimen.
    • EditedPatientsParticipants must have received no more than two prior chemotherapy regimens for advanced disease.
    • RemovedWomen must be postmenopausal due to surgical or natural menopause.
    Exclusion criteria
    • EditedPatientsParticipants with known symptomatic brain metastases requiring steroids (above physiologic replacement doses). Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to first dose of study drug, have discontinued high-dose corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable as judged by the Investigator.
    Primary outcomes 1 edited, 5 added, 6 removed
    What changed in the outcomes
    • EditedPart A: IncidenceNumber of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of ARV-471TreatmentTime frame: 28 Days → Baseline (Day 1) up to C1D28
    • AddedPart A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)
    • AddedPart B: Clinical Benefit Rate (CBR)Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
    • AddedPart C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of TreatmentTime frame: Baseline (Day 1) up to C1D28
    • AddedPart C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)
    • AddedPart C: Maximum Tolerated Dose (MTD)Time frame: Baseline (Day 1) up to C1D28
    • RemovedPart A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-471Time frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration
    • RemovedPart A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-471Time frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration
    • RemovedPart B: Assessment of anti-tumor activity of ARV-471Time frame: through study completion, up to approximately 2 years
    • RemovedPart C: Incidence of Dose Limiting Toxicities of combination ARV-471 + palbociclibTime frame: 28 Days
    • RemovedPart C: Number of Patients with Adverse Events as a measure of safety and tolerability of combination ARV-471 + palbociclibTime frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration
    • RemovedPart C: Incidence of laboratory abnormalities as a measure of safety and tolerability of combination ARV-471 + palbociclibTime frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration
    Secondary outcomes 4 edited, 26 added, 27 more
    What changed in the outcomes
    • EditedPart A: AssessmentArea Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of pharmacokinetic (PK) parameter area under the concentrationVepdegestrant and Its Epimer ARV-time curve (AUC).473Time frame: At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of ARV-471 → Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1.
    • EditedPart B: Evaluation of PlasmaPre-dose Concentrations of Vepdegestrant and Its Epimer ARV-471473Time frame: At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products] → Predose on C1D15 and C1D28 to C26D28
    • EditedPart B: EvaluationDuration of Safety and TolerabilityResponseTime frame: First study drug dose through a minimum of 30 calendar Days After Last study drug administration → From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 2 years and 11 months)
    • EditedPart C:Assessment Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of pharmacokinetic parameter area under the concentration-time curve (AUC)Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: At predefined intervals throughout the ARV-471 treatment period, up to approximately 4 weeks after last dose of investigational products → Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
    • AddedPart A: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant and Its Epimer ARV-473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
    • AddedPart A: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant and Its Epimer ARV-473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
    • AddedPart A: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant and Its Epimer ARV- 473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
    • AddedPart A: Apparent Oral Plasma Clearance (CL/F) of VepdegestrantTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
    • AddedPart A: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant and Its Epimer ARV- 473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
    • AddedPart A: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant and Its Epimer ARV- 473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
    • AddedPart A: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant and Its Epimer ARV- 473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
    • AddedPart A: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) of Vepdegestrant and Its Epimer ARV-473Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
    • AddedPart A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for Cmax (MRCmax).Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
    • AddedPart A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for AUCtau (MRAUCtau)Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
    • AddedPart A: Overall Response Rate (ORR) by Investigator Per RECIST v1.1Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
    • AddedPart A: Clinical Benefit Rate (CBR)Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
    • AddedPart A: Disease Control Rate (DCR)Time frame: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
    • AddedPart A: Progression-Free Survival (PFS) Per RECIST v1.1Time frame: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
    • AddedPart A: Duration of ResponseTime frame: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 4 years and 6 months)
    • AddedPart B: Overall Response Rate (ORR) by Investigator Per RECIST v1.1Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
    • AddedPart B: Progression-Free Survival (PFS) Per RECIST v1.1Time frame: From start of study treatment up to progressive disease or death (up to approximately 2 years and 11 months)
    • AddedPart B: Overall SurvivalTime frame: From start of study treatment up to death (up to approximately 2 years and 11 months)
    • AddedPart B: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEsTime frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 2 years and 11 months)
    • AddedPart C: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
    • AddedPart C: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
    • AddedPart C: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
    • AddedPart C: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
    • AddedPart C: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
    • AddedPart C: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
    • AddedPart C: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant, Its Epimer ARV-473 and PalbociclibTime frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
    • …and 27 more, on the record history on ClinicalTrials.gov ↗
    Interventions Changed ARV-471→Vepdegestrant; ARV-471 in combination with palbociclib (IBRANCE®)→Palbociclib. Added Drug: Vepdegestrant. Arms added: Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)·Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)·Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)·Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)·Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)·and 11 more
    All 16

    Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) · Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) · Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)

    ; arms removed: ARV-471·ARV-471 and palbociclib (IBRANCE®)
    Title A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in PatientsParticipants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
    + 4 other changes: verification date, registry dates, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04072952
Lead sponsor
Arvinas Estrogen Receptor, Inc.
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Sep 22, 2019
Primary completion
Sep 13, 2024
Completion
Mar 5, 2026
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepdegestrant

Start the discussion